Recent Progress in Allergen Immunotherapy

Area of Science:

• Immunology and Allergy Research
• Cellular and Molecular Mechanisms of Allergic Diseases

Background:

• Allergen immunotherapy (AIT) is proven effective for allergic rhinoconjunctivitis, asthma, and anaphylaxis from insect stings.
• AIT modifies T-helper 2 (TH2) responses towards T-helper 1 (TH1) and increases interleukin-10 (IL-10) synthesis by regulatory T cells (TRegs).

Purpose of the Study:

• To review current understanding of allergic disease mechanisms.
• To explore innovative immunotherapy approaches for improved allergy management.

Main Methods:

• Review of placebo-controlled trials on allergen immunotherapy.
• Exploration of novel immunotherapy strategies including peptide-based allergens and adjuvants.
• Evaluation of anti-immunoglobulin E (anti-IgE) therapy, specifically omalizumab.

Main Results:

• Novel immunotherapies aim to reduce cytokine synthesis while increasing IL-10.
• Adjuvants like CpG enhance TH1 responses.
• Omalizumab is effective for allergic asthma and rhinitis.
• Combination therapy of AIT and omalizumab shows enhanced efficacy and immune-modifying effects, potentially accelerating TReg induction.

Conclusions:

• Allergic diseases may stem from insufficient allergen-specific TReg cells.
• Future therapies should focus on inducing TReg cells that produce IL-10.
• Combination of AIT with anti-IgE offers a promising strategy for improved allergic disease treatment.